Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain
Open Access
- 4 September 2023
- Vol. 8 (5) , 101617
Abstract
No abstract availableKeywords
Funding Information
- SkylineDx
- Sanofi
- Les Laboratories Pierre Fabre
This publication has 9 references indexed in Scilit:
- Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forwardThe Lancet Global Health, 2022
- Prioritising systemic cancer therapies applying ESMO’s tools and other resources to assist in improving cancer care globally: the Kazakh experienceESMO Open, 2022
- WHO-ESMO collaboration in cancer control: policies into action to save livesESMO Open, 2022
- The Lancet Commission on diagnostics: advancing equitable access to diagnosticsThe Lancet, 2019
- ESMO-Magnitude of Clinical Benefit Scale version 1.1Annals of Oncology, 2017
- Back to the ‘essence’ of medical treatment in oncology: the 2015 WHO Model List of Essential MedicinesESMO Open, 2016
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)Annals of Oncology, 2015
- 25 years of the WHO essential medicines lists: progress and challengesThe Lancet, 2003
- Accountability for reasonablenessBMJ, 2000